Dados B3 › RSUL4 × EMBJ3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | RSUL4 | EMBJ3 | year |
|---|---|---|---|
| ROE | 0.0% | 10.3% | 2025 |
| ROIC | 30.9% | 15.5%! | 2025 |
| ROA | 15.2% | 2.8% | 2025 |
| Gross margin | 42.0% | 17.6% | 2025 |
| EBIT margin | 22.5% | 8.0% | 2025 |
| Net margin | 15.3% | 4.8% | 2025 |
| Net debt/EBITDA | -0.58x | -0.04x | 2025 |
| Current ratio | 2.74x | 1.50x | 2025 |
| Revenue growth (1y) | 10.4% | 18.2% | 2025 |
| Revenue growth (5y CAGR) | 16.6% | 16.4% | 2025 |
| Piotroski F-Score | 5/9 | 8/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | RSUL4 | EMBJ3 | year |
|---|---|---|---|
| P/E | — | 29.66x | 2025 |
| P/B | 1.33x | 3.06x | 2025 |
| EV/EBITDA | 2.99x | 12.06x | 2025 |
| FCF yield | 11.5% | 3.1% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:14 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it